Quantcast

Latest Clinical trial Stories

2014-07-11 08:24:57

SYDNEY and BEDMINSTER, N.J., July 11, 2014 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today provided feedback on its 9 July End-of-Review (EOR) meeting with the United States Food and Drug Administration (FDA). The meeting was held to discuss the feasibility and requirements for approving Moxduo, an immediate release Dual Opioid(®), for the treatment of moderate to severe acute pain. In advance of the meeting, QRxPharma outlined several questions to discuss with...

2014-07-10 10:28:40

Boston Children's Hospital Study calls for more focus on long-term outcomes in pediatric trials of drugs intended for chronic use Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events, researchers at Boston Children's Hospital report today in PLOS ONE. The study highlights...

2014-07-09 23:06:47

Patented Smart Pill Bottle Company Will Use Capital to Scale the Product and Service New York, NY (PRWEB) July 09, 2014 AdhereTech (AdhereTech.com), a healthcare technology company that makes patented smart pill bottles to improve medication adherence and patient engagement, today announced its initial closing of $1.75 million in Series A financing. The round was led by undisclosed investors with a focus in healthcare. AdhereTech will use the investment to scale its service and meet the...

2014-07-09 16:28:10

Study calls for more focus on long-term outcomes in pediatric trials of drugs intended for chronic use BOSTON, July 9, 2014 /PRNewswire-USNewswire/ -- Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events, researchers at Boston Children's Hospital report today in PLOS...

2014-07-07 16:24:20

- MPS IV A patients and families urge swift, publicly funded access to life-altering drug VIMIZIM(TM) - VANCOUVER, July 7, 2014 /CNW/ - The Canadian Society for Mucopolysaccharide & Related Diseases Inc. (Canadian MPS Society) is thrilled by Health Canada's recent approval of VIMIZIM(TM) (elosulfase alfa), the first and only pharmaceutical treatment option available for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis IVA (MPS...

2014-07-07 04:20:56

- MAA submission triggers $5 million milestone payment to AcelRx REDWOOD CITY, Calif. and AACHEN, Germany, July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO(TM) for the management of moderate to severe acute pain in adult patients in a medically supervised environment. ZALVISO(TM) is a drug-device...

2014-07-05 23:00:05

ResearchMoz.us includes new market research report, "Paralysis Global Clinical Trials Review, H1, 2014," to its huge collection of research reports. Albany,New York (PRWEB) July 06, 2014 "Paralysis Global Clinical Trials Review, H1, 2014" provides data on the paralysis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on paralysis. It includes an overview of the trial numbers and their recruitment status as per...

2014-07-03 12:39:55

Cleveland Clinic Analysis of clinical trials shows pipeline for therapeutics is small; 99.6 percent of drug attempts fail Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments. The paper, "Alzheimer's Disease Drug Development...

2014-07-02 23:11:59

Medrio’s M-1 is Ideal for Phase 1 Trials San Francisco, CA (PRWEB) July 02, 2014 Medrio, a provider of eClinical Software As A Service (SaaS) for clinical research, announced its M-1 product while an exhibitor at both DIA 2014 and BIO 2014. The two conferences brought together industry leaders across pharmaceutical and biotech fields for back to back weeks in San Diego. BIO and DIA’s positive impact on Medrio was evident as hundreds of companies, including sponsors and CROs, visited...

2014-07-02 23:03:52

MarketOptimizer.org adds “Paralysis Global Clinical Trials Review, H1, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Paralysis. Dallas, Texas (PRWEB) July 02, 2014 Clinical trial report, “Paralysis Global Clinical Trials Review, H1, 2014″ provides data on the Paralysis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Paralysis. It includes an overview of the...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.